Schochter, F., Rack, B. K., Tzschaschel, M., Polasik, A., Andergassen, U., Trapp, E., . . . Friedl, T. W. P. (2018). Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells: First results of the SUCCESS C endocrine treatment sub-study. Oncology research and treatment, 41(3), . https://doi.org/10.1159/000485566
Chicago-Zitierstil (17. Ausg.)Schochter, Fabienne, et al. "Endocrine Treatment with 2 Years of Tamoxifen Versus 2 Years of Exemestane in Postmenopausal Patients with High-risk Early Breast Cancer and Persisting Circulating Tumor Cells: First Results of the SUCCESS C Endocrine Treatment Sub-study." Oncology Research and Treatment 41, no. 3 (2018). https://doi.org/10.1159/000485566.
MLA-Zitierstil (9. Ausg.)Schochter, Fabienne, et al. "Endocrine Treatment with 2 Years of Tamoxifen Versus 2 Years of Exemestane in Postmenopausal Patients with High-risk Early Breast Cancer and Persisting Circulating Tumor Cells: First Results of the SUCCESS C Endocrine Treatment Sub-study." Oncology Research and Treatment, vol. 41, no. 3, 2018, https://doi.org/10.1159/000485566.